Exit

Health Condition

Metabolic Syndrome

About This Condition

Metabolic syndrome is a group of health risk factors that often occur together and increase the likelihood of heart disease and type 2 diabetes. The risk factors that make up metabolic syndrome include high blood glucose levels, high blood pressure, high waist circumference or waist-to-hip ratio, low HDL-cholesterol levels, and high triglyceride levels. A diagnosis of metabolic syndrome is made if a person has three or more of these conditions, and the more aspects of metabolic syndrome a person has, the greater their risk of type 2 diabetes, atherosclerosis, heart attack, and stroke.1,2 In addition, metabolic syndrome is associated with increased risks of fatty liver disease, chronic kidney disease, Alzheimer’s disease and other forms of dementia, and cancer.3,4,5,6 Women with polycystic ovary syndrome (PCOS) frequently develop a similar group of metabolic disturbances.7

It is now widely accepted that the interrelationship between insulin resistance and malfunctioning fat tissue underlies metabolic syndrome. Insulin resistance occurs when insulin is no longer effective at getting cells to respond to rising glucose levels. Over time, insulin resistance causes impaired functioning of fat cells, which play a critical role in regulating metabolism. Expansion of malfunctioning fat tissue, particularly in the abdomen, further reduces sensitivity to insulin signaling. Together, these conditions lead to chronically increased production of tissue-damaging inflammatory chemicals. This chronic inflammatory state is linked to progressive injury to the inner lining of the blood vessels and to organs and tissues throughout the body.3,9,10

In addition to the recommendations discussed below, people with metabolic syndrome may benefit from some of the recommendations given for type 2 diabetes and cardiovascular disease, as well as obesity, high cholesterol and triglyceride levels, and hypertension.

References

1. Sherling D, Perumareddi P, Hennekens C. Metabolic Syndrome. J Cardiovasc Pharmacol Ther 2017;22:365–7.

2. Saklayen M. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep 2018;20:12.

3. Zafar U, Khaliq S, Ahmad H, et al. Metabolic syndrome: an update on diagnostic criteria, pathogenesis, and genetic links. Hormones (Athens) 2018;17:299–313.

4. Rojas-Gutierrez E, Munoz-Arenas G, Trevino S, et al. Alzheimer's disease and metabolic syndrome: A link from oxidative stress and inflammation to neurodegeneration. Synapse 2017;71:e21990.

5. Atti A, Valente S, Iodice A, et al. Metabolic Syndrome, Mild Cognitive Impairment, and Dementia: A Meta-Analysis of Longitudinal Studies. Am J Geriatr Psychiatry 2019;27:625–37.

6. Uzunlulu M, Telci Caklili O, Oguz A. Association between Metabolic Syndrome and Cancer. Ann Nutr Metab 2016;68:173–9.

7. Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences. Metabolism. 2018;86:33-43.

8. Armani A, Berry A, Cirulli F, Caprio M. Molecular mechanisms underlying metabolic syndrome: the expanding role of the adipocyte. Faseb j 2017;31:4240–55.

9. van Greevenbroek M, Schalkwijk C, Stehouwer C. Dysfunctional adipose tissue and low-grade inflammation in the management of the metabolic syndrome: current practices and future advances. F1000Res 2016;5.

10. Aboonabi A, Meyer R, Singh I, Aboonabi A. Anthocyanins reduce inflammation and improve glucose and lipid metabolism associated with inhibiting nuclear factor-kappaB activation and increasing PPAR-gamma gene expression in metabolic syndrome subjects. Free Radic Biol Med 2020.

11. Yang L, Ling W, Du Z, et al. Effects of Anthocyanins on Cardiometabolic Health: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Adv Nutr 2017;8:684–93.

12. Tabeshpour J, Imenshahidi M, Hosseinzadeh H. A review of the effects of Berberis vulgaris and its major component, berberine, in metabolic syndrome. Iran J Basic Med Sci 2017;20:557–68.

13. Firouzi S, Malekahmadi M, Ghayour-Mobarhan M, et al. Barberry in the treatment of obesity and metabolic syndrome: possible mechanisms of action. Diabetes Metab Syndr Obes 2018;11:699–705.

14. Hu X, Zhang Y, Xue Y, et al. Berberine is a potential therapeutic agent for metabolic syndrome via brown adipose tissue activation and metabolism regulation. Am J Transl Res 2018;10:3322–9.

15. Yang J, Yin J, Gao H, et al. Berberine improves insulin sensitivity by inhibiting fat store and adjusting adipokines profile in human preadipocytes and metabolic syndrome patients. Evid Based Complement Alternat Med 2012;2012:363845.

16. Cao C, Su M. Effects of berberine on glucose-lipid metabolism, inflammatory factors and insulin resistance in patients with metabolic syndrome. Exp Ther Med 2019;17:3009–14.

17. Perez-Rubio K, Gonzalez-Ortiz M, Martinez-Abundis E, et al. Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord 2013;11:366–9.

18. Mollazadeh H, Hosseinzadeh H. Cinnamon effects on metabolic syndrome: a review based on its mechanisms. Iran J Basic Med Sci 2016;19:1258–70.

19. Shen Y, Jia L, Honma N, et al. Beneficial effects of cinnamon on the metabolic syndrome, inflammation, and pain, and mechanisms underlying these effects - a review. J Tradit Complement Med 2012;2:27–32.

20. Gupta Jain S, Puri S, Misra A, et al. Effect of oral cinnamon intervention on metabolic profile and body composition of Asian Indians with metabolic syndrome: a randomized double -blind control trial. Lipids Health Dis 2017;16:113.

21. Vafa M, Mohammadi F, Shidfar F, et al. Effects of cinnamon consumption on glycemic status, lipid profile and body composition in type 2 diabetic patients. Int J Prev Med 2012;3:531–6.

22. Zare R, Nadjarzadeh A, Zarshenas M, et al. Efficacy of cinnamon in patients with type II diabetes mellitus: A randomized controlled clinical trial. Clin Nutr 2019;38:549–56.

23. Akilen R, Pimlott Z, Tsiami A, Robinson N. Effect of short-term administration of cinnamon on blood pressure in patients with prediabetes and type 2 diabetes. Nutrition 2013;29:1192–6.

24. Wainstein J, Stern N, Heller S, Boaz M. Dietary cinnamon supplementation and changes in systolic blood pressure in subjects with type 2 diabetes. J Med Food 2011;14:1505–10.

25. Mousavi S, Karimi E, Hajishafiee M, et al. Anti-hypertensive effects of cinnamon supplementation in adults: A systematic review and dose-response Meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr 2019:1–11.

26. Vuksan V, Sievenpiper J, Owen R, et al. Beneficial effects of viscous dietary fiber from Konjac-mannan in subjects with the insulin resistance syndrome: results of a controlled metabolic trial. Diabetes Care 2000;23:9–14.

27. Zheng J, Li H, Zhang X, et al. Prebiotic Mannan-Oligosaccharides Augment the Hypoglycemic Effects of Metformin in Correlation with Modulating Gut Microbiota. J Agric Food Chem 2018;66:5821–31.

28. Chearskul S, Sangurai S, Nitiyanant W, et al. Glycemic and lipid responses to glucomannan in Thais with type 2 diabetes mellitus. J Med Assoc Thai 2007;90:2150–7.

29. Marventano S, Salomone F, Godos J, et al. Coffee and tea consumption in relation with non-alcoholic fatty liver and metabolic syndrome: A systematic review and meta-analysis of observational studies. Clin Nutr 2016;35:1269–81.

30. Yang C, Wang H, Sheridan Z. Studies on prevention of obesity, metabolic syndrome, diabetes, cardiovascular diseases and cancer by tea. J Food Drug Anal 2018;26:1–13.

31. Hibi M, Takase H, Iwasaki M, et al. Efficacy of tea catechin-rich beverages to reduce abdominal adiposity and metabolic syndrome risks in obese and overweight subjects: a pooled analysis of 6 human trials. Nutr Res 2018;55:1–10.

32. Li X, Wang W, Hou L, et al. Does tea extract supplementation benefit metabolic syndrome and obesity? A systematic review and meta-analysis. Clin Nutr 2019.

33. Dall'Alba V, Silva F, Antonio JP, et al. Improvement of the metabolic syndrome profile by soluble fibre - guar gum - in patients with type 2 diabetes: a randomised clinical trial. Br J Nutr 2013;110:1601–10.

34. Landin K, Holm G, Tengborn L, Smith U. Guar gum improves insulin sensitivity, blood lipids, blood pressure, and fibrinolysis in healthy men. Am J Clin Nutr 1992;56:1061–5.

35. Tagliaferro V, Cassader M, Bozzo C, et al. Moderate guar-gum addition to usual diet improves peripheral sensitivity to insulin and lipaemic profile in NIDDM. Diabete Metab 1985;11:380–5.

36. de Moura R, Resende A. Cardiovascular and Metabolic Effects of Acai, an Amazon Plant. J Cardiovasc Pharmacol 2016;68:19–26.

37. Udani J, Singh B, Singh V, et al. Effects of Acai (Euterpe oleracea Mart.) berry preparation on metabolic parameters in a healthy overweight population: a pilot study. Nutr J 2011;10:45.

38. Kim H, Simbo S, Fang C, et al. Acai (Euterpe oleracea Mart.) beverage consumption improves biomarkers for inflammation but not glucose- or lipid-metabolism in individuals with metabolic syndrome in a randomized, double-blinded, placebo-controlled clinical trial. Food Funct 2018;9:3097–103.

39. Maret W. Chromium Supplementation in Human Health, Metabolic Syndrome, and Diabetes. Met Ions Life Sci 2019;19.

40. Bai J, Xun P, Morris S, et al. Chromium exposure and incidence of metabolic syndrome among American young adults over a 23-year follow-up: the CARDIA Trace Element Study. Sci Rep 2015;5:15606.

41. Nussbaumerova B, Rosolova H, Krizek M, et al. Chromium Supplementation Reduces Resting Heart Rate in Patients with Metabolic Syndrome and Impaired Glucose Tolerance. Biol Trace Elem Res 2018;183:192–9.

42. Ali A, Ma Y, Reynolds J, et al. Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus. Endocr Pract 2011;17:16–25.

43. Iqbal N, Cardillo S, Volger S, et al. Chromium picolinate does not improve key features of metabolic syndrome in obese nondiabetic adults. Metab Syndr Relat Disord 2009;7:143–50.

44. Huang H, Chen G, Dong Y, et al. Chromium supplementation for adjuvant treatment of type 2 diabetes mellitus: Results from a pooled analysis. Mol Nutr Food Res 2018;62.

45. Zozina V, Covantev S, Goroshko O, et al. Coenzyme Q10 in Cardiovascular and Metabolic Diseases: Current State of the Problem. Curr Cardiol Rev 2018;14:164–74.

46. Raygan F, Rezavandi Z, Dadkhah Tehrani S, et al The effects of coenzyme Q10 administration on glucose homeostasis parameters, lipid profiles, biomarkers of inflammation and oxidative stress in patients with metabolic syndrome. Eur J Nutr 2016;55:2357–64.

47. Mazza A, Lenti S, Schiavon L, et al. Effect of Monacolin K and COQ10 supplementation in hypertensive and hypercholesterolemic subjects with metabolic syndrome. Biomed Pharmacother 2018;105:992–6.

48. Young J, Florkowski C, Molyneux S, et al. A randomized, double-blind, placebo-controlled crossover study of coenzyme Q10 therapy in hypertensive patients with the metabolic syndrome. Am J Hypertens 2012;25:261–70.

49. Samimi M, Zarezade Mehrizi M, Foroozanfard F, et al. The effects of coenzyme Q10 supplementation on glucose metabolism and lipid profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol (Oxf) 2017;86:560–6.

50. Fathizadeh H, Milajerdi A, Reiner Z, et al. The effects of L-carnitine supplementation on glycemic control: a systematic review and meta-analysis of randomized controlled trials. Excli j 2019;18:631–43.

51. Johri A, Heyland D, Hetu M, et al. Carnitine therapy for the treatment of metabolic syndrome and cardiovascular disease: evidence and controversies. Nutr Metab Cardiovasc Dis 2014;24:808–14.

52. Alipour B, Barzegar A, Panahi F, et al. Effect of L-Carnitine Supplementation on Metabolic Status in Obese Diabetic Women with Hypocaloric Diet. Health Scope 2014;3:e14615.

53. Salehpour S, Nazari L, Hoseini S, et al. Effects of L-carnitine on Polycystic Ovary Syndrome. JBRA Assist Reprod 2019;23:392–5.

54. Severino P, Netti L, Mariani M, et al. Prevention of Cardiovascular Disease: Screening for Magnesium Deficiency. Cardiol Res Pract 2019:4874921.

55. Guerrero-Romero F, Jaquez-Chairez F, Rodriguez-Moran M. Magnesium in metabolic syndrome: a review based on randomized, double-blind clinical trials. Magnes Res 2016;29:146–53.

56. Rodriguez-Moran M, Simental-Mendia L, Gamboa-Gomez C, Guerrero-Romero F. Oral Magnesium Supplementation and Metabolic Syndrome: A Randomized Double-Blind Placebo-Controlled Clinical Trial. Adv Chronic Kidney Dis 2018;25:261–6.

57. Kim H, Kim S, Eun Y, Song S. Effects of zinc, magnesium, and chromium supplementation on cardiometabolic risk in adults with metabolic syndrome: A double-blind, placebo-controlled randomised trial. J Trace Elem Med Biol 2018;48:166–71.

58. Wojciechowska A, Osowski A, Jozwik M, et al. Inositols' Importance in the Improvement of the Endocrine-Metabolic Profile in PCOS. Int J Mol Sci 2019;20.

59. Unfer V, Facchinetti F, Orru B, et al. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocr Connect 2017;6:647–58.

60. Monastra G, Unfer V, Harrath A, Bizzarri M. Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients. Gynecol Endocrinol 2017;33:1–9.

61. Shokrpour M, Foroozanfard F, Afshar Ebrahimi F, et al. Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: a randomized controlled clinical trial. Gynecol Endocrinol 2019;35:406–11.

62. Jamilian M, Farhat P, Foroozanfard F, et al. Comparison of myo-inositol and metformin on clinical, metabolic and genetic parameters in polycystic ovary syndrome: A randomized controlled clinical trial. Clin Endocrinol (Oxf) 2017;87:194–200.

63. Tortosa-Caparros E, Navas-Carrillo D, Marin F, Orenes-Pinero E. Anti-inflammatory effects of omega 3 and omega 6 polyunsaturated fatty acids in cardiovascular disease and metabolic syndrome. Crit Rev Food Sci Nutr 2017;57:3421–9.

64. O'Mahoney L, Matu J, Price O, et al. Omega-3 polyunsaturated fatty acids favorably modulate cardiometabolic biomarkers in type 2 diabetes: a meta-analysis and meta-regression of randomized controlled trials. Cardiovasc Diabetol 2018;17:98.

65. Guo X, Li X, Shi M, Li D. n-3 Polyunsaturated Fatty Acids and Metabolic Syndrome Risk: A Meta-Analysis. Nutrients 2017;9.

66. Gao H, Geng T, Huang T, Zhao Q. Fish oil supplementation and insulin sensitivity: a systematic review and meta-analysis. Lipids Health Dis 2017;16:131.

67. Zehr K, Walker M. Omega-3 polyunsaturated fatty acids improve endothelial function in humans at risk for atherosclerosis: A review. Prostaglandins Other Lipid Mediat 2018;134:131–40.

68. Ebrahimi M, Ghayour-Mobarhan M, Rezaiean S, et al. Omega-3 fatty acid supplements improve the cardiovascular risk profile of subjects with metabolic syndrome, including markers of inflammation and autoimmunity. Acta Cardiol 2009;64:321–7.

69. Tierney A, McMonagle J, Shaw D, et al. Effects of dietary fat modification on insulin sensitivity and on other risk factors of the metabolic syndrome--LIPGENE: a European randomized dietary intervention study. Int J Obes (Lond) 2011;35:800–9.

70. Shabrina A, Tung T, Nguyen N, et al. n-3 PUFA and caloric restriction diet alters lipidomic profiles in obese men with metabolic syndrome: a preliminary open study. Eur J Nutr 2019.

71. Asbaghi O, Choghakhori R, Abbasnezhad A. Effect of Omega-3 and vitamin E co-supplementation on serum lipids concentrations in overweight patients with metabolic disorders: A systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Syndr 2019;13:2525–31.

72. Louis-Jean S, Martirosyan D. Nutritionally Attenuating the Human Gut Microbiome to Prevent and Manage Metabolic Syndrome. J Agric Food Chem 2019;67:12675–84.

73. Kassaian N, Feizi A, Aminorroaya A, Amini M. Probiotic and synbiotic supplementation could improve metabolic syndrome in prediabetic adults: A randomized controlled trial. Diabetes Metab Syndr 2019;13:2991–6.

74. Tenorio-Jimenez C, Martinez-Ramirez M, Gil A, Gomez-Llorente C. Effects of Probiotics on Metabolic Syndrome: A Systematic Review of Randomized Clinical Trials. Nutrients 2020;12.

75. Tenorio-Jimenez C, Martinez-Ramirez M, Del Castillo-Codes I, et al. Lactobacillus reuteri V3401 Reduces Inflammatory Biomarkers and Modifies the Gastrointestinal Microbiome in Adults with Metabolic Syndrome: The PROSIR Study. Nutrients 2019;11.

76. Ferrarese R, Ceresola E, Preti A, Canducci F. Probiotics, prebiotics and synbiotics for weight loss and metabolic syndrome in the microbiome era. Eur Rev Med Pharmacol Sci 2018;22:7588–605.

77. Moukayed M, Grant W. Linking the metabolic syndrome and obesity with vitamin D status: risks and opportunities for improving cardiometabolic health and well-being. Diabetes Metab Syndr Obes 2019;12:1437–47.

78. Sacerdote A, Dave P, Lokshin V, Bahtiyar G. Type 2 Diabetes Mellitus, Insulin Resistance, and Vitamin D. Curr Diab Rep 2019;19:101.

79. Wimalawansa S. Associations of vitamin D with insulin resistance, obesity, type 2 diabetes, and metabolic syndrome. J Steroid Biochem Mol Biol 2018;175:177–89.

80. Grober U, Holick M. Diabetes Prevention: Vitamin D Supplementation May Not Provide Any Protection If There Is No Evidence of Deficiency! Nutrients 2019;11.

81. Sanchez M, de la Sierra A, Coca A, Oral calcium supplementation reduces intraplatelet free calcium concentration and insulin resistance in essential hypertensive patients. Hypertension 1997;29:531-6.

82. Devaraj S, Leonard S, Traber M, Jialal I. Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome. Free Radic Biol Med 2008;44:1203–8.

83. Heng K, Hejar A, Stanslas J, et al. Potential of mixed tocotrienol supplementation to reduce cholesterol and cytokines level in adults with metabolic syndrome. Biology 2015;21:231–43.

84. Wong S, Chin K, Suhaimi F, et al. Vitamin E as a Potential Interventional Treatment for Metabolic Syndrome: Evidence from Animal and Human Studies. Front Pharmacol 2017;8:444.

85. Ruz M, Carrasco F, Rojas P, et al. Nutritional Effects of Zinc on Metabolic Syndrome and Type 2 Diabetes: Mechanisms and Main Findings in Human Studies. Biol Trace Elem Res 2019;188:177–88.

86. Bulka C, Persky V, Daviglus M, et al. Multiple metal exposures and metabolic syndrome: A cross-sectional analysis of the National Health and Nutrition Examination Survey 2011-2014. Environ Res 2019;168:397–405.

87. Khazdouz M, Djalalinia S, Sarrafi Zadeh S, et al. Effects of Zinc Supplementation on Cardiometabolic Risk Factors: a Systematic Review and Meta-analysis of Randomized Controlled Trials. Biol Trace Elem Res 2019.

88. Wojcik J, Aukema H, Zahradka P, Taylor C. Effects of high protein diets on metabolic syndrome parameters. Curr Opin Food Sci 2016;8:43–9.

89. Hruby A, Jacques P. Dietary protein and changes in markers of cardiometabolic health across 20 years of follow-up in middle-aged Americans. Public Health Nutr 2018;21:2998–3010.

90. Campos-Nonato I, Hernandez L, Barquera S. Effect of a High-Protein Diet versus Standard-Protein Diet on Weight Loss and Biomarkers of Metabolic Syndrome: A Randomized Clinical Trial. Obes Facts 2017;10:238–51.

91. Hill A, Harris Jackson K, Roussell M, et al. Type and amount of dietary protein in the treatment of metabolic syndrome: a randomized controlled trial. Am J Clin Nutr 2015;102:757–70.

92. de la Iglesia R, Loria-Kohen V, Zulet M, et al. Dietary Strategies Implicated in the Prevention and Treatment of Metabolic Syndrome. Int J Mol Sci 2016;17.

93. Zhang J, Jiang Y, Liu Y, et al. The association between glycemic index, glycemic load, and metabolic syndrome: a systematic review and dose-response meta-analysis of observational studies. Eur J Nutr 2019.

94. Shahdadian F, Saneei P, Milajerdi A, Esmaillzadeh A. Dietary glycemic index, glycemic load, and risk of mortality from all causes and cardiovascular diseases: a systematic review and dose-response meta-analysis of prospective cohort studies. Am J Clin Nutr 2019;110:921–37.

95. Cano-Ibanez N, Bueno-Cavanillas A, Martinez-Gonzalez M, et al. Effect of changes in adherence to Mediterranean diet on nutrient density after 1-year of follow-up: results from the PREDIMED-Plus Study. Eur J Nutr 2019.

96. Franquesa M, Pujol-Busquets G, Garcia-Fernandez E, et al. Mediterranean Diet and Cardiodiabesity: A Systematic Review through Evidence-Based Answers to Key Clinical Questions. Nutrients 2019;11.

97. Carlos S, De La Fuente-Arrillaga C, Bes-Rastrollo M, et al. Mediterranean Diet and Health Outcomes in the SUN Cohort. Nutrients 2018;10.

98. Kargin D, Tomaino L, Serra-Majem L. Experimental Outcomes of the Mediterranean Diet: Lessons Learned from the Predimed Randomized Controlled Trial. Nutrients 2019;11.

99. Pavic E, Hadziabdic M, Mucalo I, et al. Effect of the Mediterranean diet in combination with exercise on metabolic syndrome parameters: 1-year randomized controlled trial. Int J Vitam Nutr Res 2019;89:132–43.

100. Gepner Y, Shelef I, Komy O, et al. The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content. J Hepatol 2019;71:379–88.

101. Santulli G, Pascale V, Finelli R, et al. We are What We Eat: Impact of Food from Short Supply Chain on Metabolic Syndrome. J Clin Med 2019;8.

102. Clifton P. Metabolic Syndrome-Role of Dietary Fat Type and Quantity. Nutrients 2019;11.

103. Julibert A, Bibiloni M, Bouzas C, et al. Total and Subtypes of Dietary Fat Intake and Its Association with Components of the Metabolic Syndrome in a Mediterranean Population at High Cardiovascular Risk. Nutrients 2019;11.

104. Drehmer M, Pereira MA, Schmidt MI, et al. Total and Full-Fat, but Not Low-Fat, Dairy Product Intakes are Inversely Associated with Metabolic Syndrome in Adults. J Nutr 2016;146:81–9.

105. Unger A, Torres-Gonzalez M, Kraft J. Dairy Fat Consumption and the Risk of Metabolic Syndrome: An Examination of the Saturated Fatty Acids in Dairy. Nutrients 2019;11.

106. Kim Y, Xun P, Iribarren C, et al. Intake of fish and long-chain omega-3 polyunsaturated fatty acids and incidence of metabolic syndrome among American young adults: a 25-year follow-up study. Eur J Nutr 2016;55:1707–16.

107. Liu Y, Wu Q, Xia Y, et al. Carbohydrate intake and risk of metabolic syndrome: A dose-response meta-analysis of observational studies. Nutr Metab Cardiovasc Dis 2019;29:1288–98.

108. Hashimoto Y, Tanaka M, Miki A, et al. Intake of Carbohydrate to Fiber Ratio Is a Useful Marker for Metabolic Syndrome in Patients with Type 2 Diabetes: A Cross-Sectional Study. Ann Nutr Metab 2018;72:329–35.

109. Hyde P, Sapper T, Crabtree C, et al. Dietary carbohydrate restriction improves metabolic syndrome independent of weight loss. JCI Insight 2019;4.

110. Gershuni V, Yan S, Medici V. Nutritional Ketosis for Weight Management and Reversal of Metabolic Syndrome. Curr Nutr Rep 2018;7:97–106.

111. Cicero A, Benelli M, Brancaleoni M, et al. Middle and Long-Term Impact of a Very Low-Carbohydrate Ketogenic Diet on Cardiometabolic Factors: A Multi-Center, Cross-Sectional, Clinical Study. High Blood Press Cardiovasc Prev 2015;22:389–94.

112. Paoli A, Mancin L, Bianco A, et al. Ketogenic Diet and Microbiota: Friends or Enemies? Genes (Basel) 2019;10.

113. Caprio M, Infante M, Moriconi E, et al. Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian Society of Endocrinology (SIE). J Endocrinol Invest 2019;42:1365–86.

114. Kosinski C, Jornayvaz F. Effects of Ketogenic Diets on Cardiovascular Risk Factors: Evidence from Animal and Human Studies. Nutrients 2017;9.

115. Noto H, Goto A, Tsujimoto T, Noda M. Low-carbohydrate diets and all-cause mortality: a systematic review and meta-analysis of observational studies. PLoS One 2013;8:e55030.

116. Seidelmann S, Claggett B, Cheng S, et al. Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis. Lancet Public Health 2018;3:e419–28.

117. Smith GI, Mittendorfer B, Klein S. Metabolically healthy obesity: facts and fantasies. J Clin Invest 2019;129:3978–89.

118. Tajik S, Mirzababaei A, Ghaedi E, et al. Risk of type 2 diabetes in metabolically healthy people in different categories of body mass index: an updated network meta-analysis of prospective cohort studies. J Cardiovasc Thorac Res 2019;11:254–63.

119. Cao Q, Yu S, Xiong W, et al. Waist-hip ratio as a predictor of myocardial infarction risk: A systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e11639.

120. Engin A. The Definition and Prevalence of Obesity and Metabolic Syndrome. Adv Exp Med Biol 2017;960:1–17.

121. Ryan D, Yockey S. Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over. Curr Obes Rep 2017;6:187–94.

122. Gallardo-Alfaro L, Bibiloni M, Mateos D, et al. Leisure-Time Physical Activity and Metabolic Syndrome in Older Adults. Int J Environ Res Public Health 2019;16.

123. Grazioli E, Dimauro I, Mercatelli N, et al. Physical activity in the prevention of human diseases: role of epigenetic modifications. BMC Genomics 2017;18:802.

124. Joseph M, Tincopa M, Walden P, et al. The Impact Of Structured Exercise Programs On Metabolic Syndrome And Its Components: A Systematic Review. Diabetes Metab Syndr Obes 2019;12:2395–404.

125. Myers J, Kokkinos P, Nyelin E. Physical Activity, Cardiorespiratory Fitness, and the Metabolic Syndrome. Nutrients 2019;11.

126. Wewege M, Thom J, Rye K, Parmenter B. Aerobic, resistance or combined training: A systematic review and meta-analysis of exercise to reduce cardiovascular risk in adults with metabolic syndrome. Atherosclerosis 2018;274:162–71.

127. Ostman C, Smart N, Morcos D, et al. The effect of exercise training on clinical outcomes in patients with the metabolic syndrome: a systematic review and meta-analysis. Cardiovasc Diabetol 2017;16:110.

128. Bergmann N, Gyntelberg F, Faber J. The appraisal of chronic stress and the development of the metabolic syndrome: a systematic review of prospective cohort studies. Endocr Connect 2014;3:R55–80.

129. Ortiz M, Sapunar J. Longitudinal association between chronic psychological stress and metabolic syndrome. Rev Med Chil 2018;146:1278–85.

130. Morera L, Marchiori G, Medrano L, Defago M. Stress, Dietary Patterns and Cardiovascular Disease: A Mini-Review. Front Neurosci 2019;13:1226.

131. Onyango A. Cellular Stresses and Stress Responses in the Pathogenesis of Insulin Resistance. Oxid Med Cell Longev 2018;2018:4321714.

132. Chan K, Cathomas F, Russo S. Central and Peripheral Inflammation Link Metabolic Syndrome and Major Depressive Disorder. Physiology (Bethesda) 2019;34:123–33.

133. Daubenmier J, Moran P, Kristeller J, et al. Effects of a mindfulness-based weight loss intervention in adults with obesity: A randomized clinical trial. Obesity (Silver Spring) 2016;24:794–804.

134. Daubenmier J, Kristeller J, Hecht F, et al. Mindfulness Intervention for Stress Eating to Reduce Cortisol and Abdominal Fat among Overweight and Obese Women: An Exploratory Randomized Controlled Study. J Obes 2011;2011:651936.

135. Artese A, Stamford B, Moffatt R. Cigarette Smoking: An Accessory to the Development of Insulin Resistance. Am J Lifestyle Med 2019;13:602–5.

136. Frigerio B, Werba J, Amato M, et al. Traditional Risk Factors are Causally Related to Carotid Intima-Media Thickness Progression: Inferences from Observational Cohort Studies and Interventional Trials. Curr Pharm Des 2019.

137. Yankey B, Strasser S, Okosun I. A cross-sectional analysis of the association between marijuana and cigarette smoking with metabolic syndrome among adults in the United States. Diabetes Metab Syndr 2016;10:S89–95.

138. Ponciano-Rodriguez G, Paez-Martinez N, Villa-Romero A, et al. Early changes in the components of the metabolic syndrome in a group of smokers after tobacco cessation. Metab Syndr Relat Disord 2014;12:242–50.

139. Song Y, Chang W, Hsu H, Chen M. A short-term smoking cessation may increase the risk of developing metabolic syndrome. Diabetes Metab Syndr 2015;9:135–7.

140. Eliasson B, Taskinen M, Smith U. Long-term use of nicotine gum is associated with hyperinsulinemia and insulin resistance. Circulation 1996;94:878–81.

141. Boyle M, Masson S, Anstee Q. The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease. J Hepatol 2018;68:251–67.

142. Mahli A, Hellerbrand C. Alcohol and Obesity: A Dangerous Association for Fatty Liver Disease. Dig Dis 2016;34 Suppl 1:32–9.

143. Aberg F, Farkkila M, Mannisto V. Interaction Between Alcohol Use and Metabolic Risk Factors for Liver Disease: A Critical Review of Epidemiological Studies. Alcohol Clin Exp Res 2020;44:384–403.

144. Du D, Bruno R, Dwyer T, et al. Associations between alcohol consumption and cardio-metabolic risk factors in young adults. Eur J Prev Cardiol 2017;24:1967–78.

145. Hirakawa M, Arase Y, Amakawa K, et al. Relationship between Alcohol Intake and Risk Factors for Metabolic Syndrome in Men. Intern Med 2015;54:2139–45.

146. Huang J, Wang X, Zhang Y. Specific types of alcoholic beverage consumption and risk of type 2 diabetes: A systematic review and meta-analysis. J Diabetes Investig 2017;8:56–68.

147. Piano M. Alcohol's Effects on the Cardiovascular System. Alcohol Res 2017;38:219–41.

Copyright © 2020 Healthnotes, Inc. All rights reserved. www.healthnotes.com

Learn more about Healthnotes, the company.

The information presented by Healthnotes is for informational purposes only. It is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. Self-treatment is not recommended for life-threatening conditions that require medical treatment under a doctor's care. For many of the conditions discussed, treatment with prescription or over the counter medication is also available. Consult your doctor, practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications. Information expires December 2020.

Drugs used to treat INSULIN RESISTANCE SYNDROME. Select drug name to view medication information and pricing